Literature DB >> 28373830

Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions.

Agnieszka Jezierska1, Irina A Kolosova2, Alexander D Verin3.   

Abstract

This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohn's disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.

Entities:  

Keywords:  TLR; signaling pathways; therapy

Year:  2011        PMID: 28373830      PMCID: PMC5376075          DOI: 10.2174/157436211797483930

Source DB:  PubMed          Journal:  Curr Signal Transduct Ther        ISSN: 1574-3624


  133 in total

1.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.

Authors:  O Takeuchi; K Hoshino; T Kawai; H Sanjo; H Takada; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

Review 2.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

3.  Negative regulation of toll-like receptor-mediated signaling by Tollip.

Authors:  Guolong Zhang; Sankar Ghosh
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

4.  Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway.

Authors:  L Arbibe; J P Mira; N Teusch; L Kline; M Guha; N Mackman; P J Godowski; R J Ulevitch; U G Knaus
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

5.  Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages.

Authors:  D M Underhill; A Ozinsky; K D Smith; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

6.  TIRAP: an adapter molecule in the Toll signaling pathway.

Authors:  T Horng; G M Barton; R Medzhitov
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

7.  Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation.

Authors:  S Vlahopoulos; I Boldogh; A Casola; A R Brasier
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

Review 8.  Imiquimod applied topically: a novel immune response modifier and new class of drug.

Authors:  R L Miller; J F Gerster; M L Owens; H B Slade; M A Tomai
Journal:  Int J Immunopharmacol       Date:  1999-01

9.  Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury.

Authors:  George Tsoulfas; Yoshihito Takahashi; Raymond W Ganster; Gautam Yagnik; Zhong Guo; John J Fung; Noriko Murase; David A Geller
Journal:  Transplantation       Date:  2002-07-15       Impact factor: 4.939

10.  Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A.

Authors:  Morihito Sato; Hitomi Sano; Daisuke Iwaki; Kazumi Kudo; Masanori Konishi; Hiroki Takahashi; Toru Takahashi; Hitoshi Imaizumi; Yasufumi Asai; Yoshio Kuroki
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

View more
  7 in total

1.  TLR3/TAK1 signalling regulates rhinovirus-induced interleukin-33 in bronchial smooth muscle cells.

Authors:  Sangeetha Ramu; Jenny Calvén; Charalambos Michaeloudes; Mandy Menzel; Hamid Akbarshahi; Kian Fan Chung; Lena Uller
Journal:  ERJ Open Res       Date:  2020-10-05

Review 2.  TLRs in pulmonary diseases.

Authors:  Shweta Arora; Shaniya Ahmad; Rasha Irshad; Yamini Goyal; Sahar Rafat; Neha Siddiqui; Kapil Dev; Mohammad Husain; Shakir Ali; Anant Mohan; Mansoor Ali Syed
Journal:  Life Sci       Date:  2019-07-20       Impact factor: 5.037

Review 3.  Toll-Like Receptors in Acute Kidney Injury.

Authors:  Cristina Vázquez-Carballo; Melania Guerrero-Hue; Cristina García-Caballero; Sandra Rayego-Mateos; Lucas Opazo-Ríos; José Luis Morgado-Pascual; Carmen Herencia-Bellido; Mercedes Vallejo-Mudarra; Isabel Cortegano; María Luisa Gaspar; Belén de Andrés; Jesús Egido; Juan Antonio Moreno
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

4.  Expression of Main Toll-Like Receptors in Patients with Different Types of Colorectal Polyps and Their Relationship with Gut Microbiota.

Authors:  Sama Rezasoltani; Reza Ghanbari; Mehdi Azizmohammad Looha; Ehsan Nazemalhosseini Mojarad; Abbas Yadegar; Delisha Stewart; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

5.  Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF.

Authors:  Francesco Bonella; Ilaria Campo; Michele Zorzetto; Eda Boerner; Shinichiro Ohshimo; Dirk Theegarten; Christian Taube; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2021-02-27       Impact factor: 4.123

Review 6.  The Role of Toll-Like Receptors and Vitamin D in Cardiovascular Diseases-A Review.

Authors:  Daria M Adamczak
Journal:  Int J Mol Sci       Date:  2017-10-27       Impact factor: 5.923

7.  Short-term transcriptomic response to plasma membrane injury.

Authors:  Swantje Christin Häger; Catarina Dias; Stine Lauritzen Sønder; André Vidas Olsen; Isabelle da Piedade; Anne Sofie Busk Heitmann; Elena Papaleo; Jesper Nylandsted
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.